Post-infarction ventricular septal defect: percutaneous or surgical management in the UK national registry.

AIMS: Post-infarction ventricular septal defect (PIVSD) is a mechanical complication of acute myocardial infarction (AMI) with a poor prognosis. Surgical repair is the mainstay of treatment, although percutaneous closure is increasingly undertaken. METHODS AND RESUTS: Patients treated with surgical or percutaneous repair of PIVSD (2010-2021) were identified at 16 UK centres. Case note review was undertaken. The primary outcome was long-term mortality. Patient groups were allocated based upon initial management (percutaneous or surgical). Three-hundred sixty-two patients received 416 procedures (131 percutaneous, 231 surgery). 16.1% of percutaneous patients subsequently had surgery. 7.8% of surgical patients subsequently had percutaneous treatment. Times from AMI to treatment were similar [percutaneous 9 (6-14) vs. surgical 9 (4-22) days, P = 0.18]. Surgical patients were more likely to have cardiogenic shock (62.8% vs. 51.9%, P = 0.044). Percutaneous patients were substantially older [72 (64-77) vs. 67 (61-73) years, P < 0.001] and more likely to be discussed in a heart team setting. There was no difference in long-term mortality between patients (61.1% vs. 53.7%, P = 0.17). In-hospital mortality was lower in the surgical group (55.0% vs. 44.2%, P = 0.048) with no difference in mortality after hospital discharge (P = 0.65). Cardiogenic shock [adjusted hazard ratio (aHR) 1.97 (95% confidence interval 1.37-2.84), P < 0.001), percutaneous approach [aHR 1.44 (1.01-2.05), P = 0.042], and number of vessels with coronary artery disease [aHR 1.22 (1.01-1.47), P = 0.043] were independently associated with long-term mortality. CONCLUSION: Surgical and percutaneous repair are viable options for management of PIVSD. There was no difference in post-discharge long-term mortality between patients, although in-hospital mortality was lower for surgery.

Predicting the performance of mitral prostheses implanted in children under 5 years of age.

BACKGROUND: Mitral valve replacement (MVR) is occasionally indicated in infants and young children, necessitating the use of small prostheses. The performance of these small valves during somatic growth of the patient can lead to patient-prosthesis mismatch. This study examines performance of these valves over time to establish predicted performance and timing of replacement. METHODS: Records were reviewed of all patients under 5 years of who underwent small mechanical MVR between 1988 and 2004 (n=24). Valve sizes were between 17 and 23 mm (Bileaflet 91.6%, Tilting Disc 8.3%) with a median size of 19 mm. Mean age of patients was 1.4+/-1.3 years with a mean weight of 7.8+/-3.4 kg. RESULTS: Early deaths (n=5, 20.8%) were excluded. There were two late deaths and five patients required redo-MVR: four for outgrowth and one for acute thrombosis at 3 months. Age at redo for outgrowth was 8.6+/-6.6 years with mean body weight of 22.5+/-17.5 kg. Mean time between original operation and redo was 8.6+/-6.1 years in these four patients. Follow-up was a median of 7.5 years (range 0.1-15.7 years). Overall freedom from death or valve replacement was 82.6+/-9.1% at 5 years and 75.7+/-10.6% at 10 years. The performance of the original prostheses showed a peak blood flow velocity across the valves of 1.5+/-0.6 m/s at 5 years and 2.2+/-0.5 m/s at 10 years. Seventy-five percent of the survivors still have their original valve at a mean of 8.1+/-4.4 years postoperative with New York Heart Association status of I or II. Actuarial curves suggest that gradients across the valves reach a peak of >10 mmHg at a mean between 6.5 and 7 years postoperative. CONCLUSION: MVR in children under 5 years carries a high mortality. Nevertheless, small mechanical MVR perform remarkably well in young children with durable haemodynamics despite growth of the patients well beyond more than double the initial bodyweight. Valves can be expected to last over 8 years before requiring re-replacement.

Experience with intraoperative ultrasound in paediatric cardiac surgery.

OBJECTIVE: Intraoperative ultrasound was introduced to evaluate the adequacy of repair after surgical repair of congenital cardiac malformations. Our purpose was to review the evolution of this technique at our centre. METHODS: We evaluated all intraoperative ultrasound studies undertaken between 1997 and 2002, reviewing the data from 1997 through 2001 retrospectively, but undertaking a prospective audit of studies undertaken from 2002 onwards. In all, we carried out a total number of 639 intraoperative ultrasound studies, from a possible 2737 cardiac operations (23.3%), using the epicardial approach in 580 (90.7%), and transoesophageal ultrasound in the other 59 patients (9.3%). Median age was 0.6 years, with an interquartile range from 0.06 to 3.6 years. RESULTS: The findings obtained using intraoperative ultrasound influenced the surgical management in 63 of the 639 patients (9.9%), suggesting the need for additional surgery in 26, adjustment of the band placed round the pulmonary trunk in 16, preoperative assessment of the cardiac malformation in 5, and confirming the need for prolonged support with cardiopulmonary bypass for impaired ventricular function in 16. There were 18 early reoperations, 5 of which may have been predicted by intraoperative ultrasound. Of the 183 studies reviewed prospectively in 2002, it was not possible to obtain the complete range of views in 8 (4.4%), while in 27 patients (14.7%), the postoperative findings using transthoracic interrogation differed from the findings obtained immediately following bypass. CONCLUSION: Intraoperative ultrasound is an important technique for monitoring the results of complex congenital cardiac surgery. The immediate recognition of significant lesions, together with multidisciplinary discussion, allows for improved management and prevention of early surgical reintervention.